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MinireviewClearance of Alzheimer’s
A Peptide: The Many Roads
to Perdition
production will attenuate the formation of  amyloid
and, ultimately, slow down or halt neurodegeneration.
However, facilitation of A clearance carries the poten-
tial to be equally effective at lowering  amyloid burden.
This minireview covers the known pathways by which
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Mounting evidence suggests that the low-density lipo-
protein receptor-related protein (LRP) and the receptor
for advanced glycation end products (RAGE) are in-The amyloid hypothesis of Alzheimer’s disease (AD)
volved in receptor-mediated flux of A across the blood-maintains that the accumulation of the amyloid  pro-
brain barrier (BBB) (reviewed in Zlokovic, 2004). Bothtein (A) is a critical event in disease pathogenesis. A
LRP and RAGE are multiligand cell surface receptorsgreat deal of both academic and commercial research
that mediate the clearance of a large number of proteinshas focused on the mechanisms by which A is gener-
in addition to A. While LRP appears to mediate theated. However, investigations into the mechanisms
efflux of A from the brain to the periphery, RAGE hasunderlying A clearance have blossomed over the last
been strongly implicated in A influx back into the CNS.several years. This minireview will summarize path-
In addition, evidence also exists to suggest that 10%–ways involved in the removal of cerebral A, including
15% A can enter into the cerebral spinal fluid (CSF)enzymatic degradation and receptor-mediated efflux
from the brain interstitial fluid and onward into the blood-out of the brain.
stream (Shibata et al., 2000).
LRP is a multifunctional signaling and scavenger re-The earliest origins of the amyloid hypothesis as intro-
ceptor consisting of a heavy chain that can bind a varietyduced by George Glenner 20 years ago held that the
of ligands, e.g., apolipoprotein E (apoE), 2-macroglob-accumulation of the amyloid  protein (A) in  amyloid
ulin (2M), and APP (reviewed in Herz, 2003). A key roledeposits is the key pathological event driving neurode-
for LRP in exporting A from brain has been substanti-generation in Alzheimer’s disease (AD) (Glenner and
ated in a number of studies, most notably in animalWong, 1984). While this hypothesis has arguably been
models. LRP antagonists have been shown to specifi-robustly supported over the past two decades by ge-
cally reduce the efflux of A from brain by up to 90%netic, molecular and cell biological, biochemical, and
(Shibata et al., 2000) in mice injected with radiolabeledtransgenic studies (Hardy and Selkoe, 2002), it still re-
A40. Cerebral amyloid load was observed to be dou-mains controversial. Nonetheless, studies of the life-
bled in AD animal models that were engineered to pos-cycle of A from its generation to its metabolism have
sess low levels of LRP at the BBB, owing to knockreceived an extraordinary amount of attention in the field
out of the critical LRP chaperone, receptor-associatedof AD research for the past two decades. The A peptide
protein (RAP) (Van Uden et al., 2002). In the process ofis not produced as an independent protein entity but is
LRP-mediated clearance, A has previously been
instead generated by the proteolytic processing of a
shown to initially form a complex with the LRP ligands,
much larger transmembrane protein, the amyloid protein
2M or apoE, on the abluminal side of the endothelium.
precursor (APP) (Kang et al., 1987; Tanzi et al., 1987). The A/chaperone complex then binds to LRP and is
In simplest terms, the life-long accumulation of A in internalized. LRP-ligand complexes are then internal-
the brain is then determined by the rate of A generation ized to late endosomes after which they can either be
versus clearance. Clearance can be accomplished via delivered to lysosomes for subsequent degradation or
two major pathways: proteolytic degradation and recep- be targeted for transcytosis across the BBB into the
tor-mediated transport from the brain. plasma (Figure 1; reviewed in Herz, 2003).
Most of the 160 gene mutations in APP, presenilin Until recently, it had been assumed that A could only
1, and presenilin 2 underlying some forms of early-onset bind LRP indirectly, as part of a complex with the LRP
(60) autosomal-dominant familial Alzheimer’s disease ligands apoE and 2M. However, Zlokovic and col-
(FAD) increase the relative production of A42 (the leagues (Deane et al., 2004) have very recently provided
longer, more amyloidogenic form of the peptide). Conse- strong evidence for the direct interaction of LRP and A
quently, factors involved in modulating A levels and on brain capillaries. In a departure from the chaperone-
particular isoforms of the peptide, e.g, A42, have been mediated clearance mode, the new data indicate that
most intensely studied during the last decade. The ma- A can be transported across the BBB and be cleared
jority of these studies have focused on processes in- from the brain after directly binding to LRP. The same
volved in A production, particularly on the activities of study reports that LRP, located at the BBB, favors clear-
-, and -secretase, which cleave APP to liberate A. ance of A40 over the much more amyloidogenic spe-
The rationale for this approach is that a reduction in A cies of the peptide, A42. LRP also favors A40 over a
more amyloidogenic, mutant form of A containing two
APP gene mutations (Dutch and Iowa) known to cause*Correspondence: tanzi@helix.mgh.harvard.edu
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(Yan et al., 2000). One of these ligands is A, for which
RAGE has an affinity in the nanomolar range. This sup-
ports the possibility for an endogenous physiological
interaction between A and RAGE. Indeed, data from
animal models have shown that downregulation of
RAGE is able to inhibit the influx of A from the periphery
into the CNS (Deane et al., 2003). It is also worth noting
that the binding of A to RAGE has been shown to
stimulate cellular responses that are potentially patho-
logical, including expression of proinflammatory cyto-
kines and decreased cerebral blood flow (reviewed in
Zlokovic, 2004).
Besides RAGE, gp330/megalin has also been reported
to transport circulating plasma A back into the brain,
in a complex with apoJ (Zlokovic et al., 1996). However,
since gp330/megalin would normally be saturated by
abundant amounts of plasma apoJ under physiological
Figure 1. Pathways Involved in Removal of Cerebral A conditions, RAGE is the most probable receptor respon-
Soluble A in the parenchyma of the brain can undergo two basic sible for transport of A back into brain (review by Zlo-
fates. It can aggregate into fibrillogenic species that can be ulti- kovic, 2004).
mately deposited as  amyloid. This is fostered by interaction with
Peptidolytic Removal of Azinc, copper, and other heavy metals. Blocking the interaction of
The two major endopeptidases involved in A degrada-Awith these metals using metal-complexing drugs, e.g., clioquinol,
tion are zinc metalloendopeptidases, referred to as insu-has been proposed as a clearance-based therapy for AD. Soluble A
can be removed from the brain via two basic pathways: enzymatic lin degrading enzyme (IDE) or insulysin, and neprilysin
degradation or receptor-mediated clearance. In the case of degra- (NEP). IDE (EC 3.4.24.56) is a 110 kDa zinc metalloendo-
dation, A can be internalized and degraded by activated micoglia peptidase that hydrolyzes several regulatory peptides
in the brain. The amyloid vaccine has been speculated to promote (for review, see Duckworth et al., 1998), including insulin,
this activity. Alternatively, soluble A can be degraded by specific
glucagon, atrial natriuretic factor, transforming growthpeptidases, such as IDE and NEP, shown here. In an alternative A
factor , -endorphin, amylin, A, and the APP intracel-clearance pathway, the peptide can be transported across the BBB
and exported out of the brain into the blood stream either by direct lular domain (AICD). Multiple lines of evidence support
binding to LRP or by first binding the LRP ligands/A chaperones a role for IDE in A degradation (reviewed in Selkoe,
apoE and 2M. Once A enters the bloodstream, it can reenter the 2001), but the most convincing evidence has come from
brain via the RAGE receptor or be delivered, e.g., via chaperone IDE knockout mice (Farris et al., 2003). These mice reveal
molecules such as apoE or 2M, to peripheral sites of degradation,
increased endogenous levels of A and AICD in thee.g., liver and kidney. Another proposed mechanism for A immuni-
brain. Additionally, heterozygous IDE/ mice exhibitzation is one in which antibodies to  amyloid bind A in the blood-
A levels that are intermediate between wild-type con-stream and prevent reentry back into the brain (the peripheral sink
hypothesis). Green arrows signify pathways that might be pharma- trols and IDE/ mice. It also has been shown that
cologically enhanced, while red arrows and slashed circles indicate primary neuronal cultures derived from these mice are
pathways that might be blocked as potential therapeutic ap- less effective at degrading radiolabeled A, in vitro.
proaches for the treatment and prevention of AD. Another recent study employing chronic transgenic
overexpression of IDE (2-fold over endogeneous) in mice
overexpressing human APP harboring both APP717 andvascular amyloidosis. The latter findings suggest that APP670/671 missense mutations revealed a 50% decrease
these mutations may not only render A more prone to in both soluble and insoluble AX-40 and AX-42 levels
amyloid formation, but may also impede efflux out of (Leissring et al., 2003). In addition, in the APP/IDE double
the brain via LRP. These data also more generally imply transgenic mice, A plaque burden was diminished by
that fibrillogenic forms of A, which accumulate in AD 50% and there was a significant reduction in the rate
brain, may be difficult to remove from the CNS via LRP. of premature death as compared to age-matched APP
Finally, the same study also shows that A can promote transgenic littermates. Collectively, these findings serve
the proteasome-dependent degradation of LRP. Based to validate a role for IDE in A degradation in vivo and
on this observation, the authors make the interesting suggest that even moderate increases in IDE activity
speculation that this may perhaps explain previous ob- can lead to dramatic changes in steady-state A levels
servations of relatively low LRP activity in brain microves- as well as overall amyloid plaque burden. Further sup-
sels in AD patients and mutant APP mouse models of port for the role of IDE in AD pathogenesis stems from
 amyloidosis. Further support for the role of LRP-medi- recent reports of its genetic association with late-onset
ated clearance of A comes from DNA variants in the AD (reviewed in Bertram and Tanzi, 2004).
genes encoding 2M, apoE, and LRP that have been The other major peptidase responsible for the degra-
previously associated with increased risk for AD (re- dation of A is NEP (EC 3.4.24.15), also referred to as
viewed in Bertram and Tanzi, 2004). neutral endopeptidase and enkephalinase. NEP is a type
While it remains unclear whether LRP also mediates II membrane protein, which like IDE hydrolyzes circulat-
A influx into brain from the bloodstream, the major ing biologically active peptides, including enkephalin,
player in this arena appears to be RAGE, a multifunc- cholecystokinin, neuropeptide Y, and substance P (for
tional receptor in the immunoglobulin superfamily, review, see Turner et al., 2001). Numerous studies have
implicated NEP as a rate-limiting A-degrading enzymewhich like LRP, binds a large array of different ligands
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in the brain, including viral expression of NEP in primary A, but can also stabilize  amyloid deposits (see review
by Bush and Tanzi, 2002). Along these lines, the metal-neurons (Hama et al., 2001), knockout studies in mice
(Iwata et al., 2001), and chronic transgenic overexpres- complexing agent clioquinol, a discontinued antibiotic,
has been shown to attenuate  amyloid deposition insion studies identical to those described above for IDE,
with the exception that the level of overexpression was mice and to lower plasma A levels and attenuate cogni-
tive decline in AD patients (Ritchie et al., 2003).8-fold for NEP as opposed to 2-fold for IDE (Leissring
et al., 2003). The intriguing localization of NEP on the The A clearance pathways illustrated in Figure 1 de-
lineate the above mentioned as well as several otherplasma membrane with its catalytic site exposed extra-
cellularly makes this peptidase a prime candidate for therapeutic opportunities for clearing cerebral A. For
example, one might consider strategies for enhancingpeptide degradation at extracellular sites of amyloid ac-
cumulation i.e., A-containing diffuse deposits and neu- the binding of A either directly to LRP or to the LRP
ligands/A chaperones apoE and 2M as a therapeuticritic plaques. In contrast, most IDE is localized in the
cytosol, while only a small fraction resides in the plasma strategy for promoting efflux of the peptide out of the
brain. Alternatively, one might envisage a pharmacologi-membrane. Recent studies employing unilateral intrace-
rebral injection of a lentiviral vector expressing human cal means for preventing the influx of plasma A back
into brain via RAGE by specifically blocking this interac-NEP in a transgenic mouse model of cerebral amy-
loidosis resulted in a remarkable 50% decrease in ipsi- tion. Alternatively, A could be removed from the CNS
or at peripheral degradation sites by enhancing the ac-lateral cortical amyloid deposits compared to the con-
tralateral cortex (Marr et al., 2003). This is the first and tivity of the major degradation enzymes IDE and NEP.
Along these lines, Song et al. (2003) have demonstratedso far only demonstration of a degradative effect by
a peptidase on a preexisting A-related pathological active site substrates for IDE that can activate the en-
zyme toward hydrolyzing A, but not insulin. In anyendpoint. Analogous studies with other bona fide metal-
loendopeptidase candidates, such as IDE and endo- clearance-based therapeutic strategy, it will be impor-
tant to remain mindful of potential physiologic roles forthelin converting enzyme or ECE, as well as properly
positioned circulating serine proteases, such as uroki- the A peptide in the brain and periphery.
Conclusionnase-type plasminogen activator (u-PA), tissue plasmin-
ogen activator (tPA), and plasmin, are likely to follow. While the majority of A-related research and pharma-
cological research and development have been primar-The latter three cases (u-PA, tPA, and plasmin) may be
expected to have a more significant impact on cerebro- ily placed on understanding how A is generated from
APP via cleavage by - and -secretase with the goalvascular amyloid deposits or congophilic amyloid angio-
pathy (for review, see Selkoe, 2001). Finally, the proteo- of curbing A production, studies and therapies aimed
at A clearance have been gaining considerable mo-some may also play a key role in degrading intracellularly
localized A, for example, as part of the process of mentum over the last several years. A number of differ-
ent molecules and pathways have been implicated inendoplasmic reticulum (ER)-associated proteolytic deg-
radation (Schmitz et al., 2004). the process of removal of cerebral A, all of which fall
into two basic categories: (1) peptidolytic and proteo-Therapies for AD Based on A Clearance
The molecular pathways responsible for efflux and influx lytic degradation of cerebral A or (2) receptor-mediated
export of A across the BBB into the plasma, where itof A across the BBB, between plasma and brain, sug-
gest an array of potential therapeutic strategies that can either be delivered to peripheral sites of degrada-
tion, e.g., kidney and liver, or gain reentry back into thecould be aimed at reducing the accumulation of cerebral
A. Most recently, immunological approaches have CNS. The major enzymes responsible for A degrada-
tion are IDE and NEP, although ECE and plasmin havebeen implemented to reduce A load in the CNS. Recent
studies have demonstrated that  amyloid burden in also been implicated. It should be noted that IDE is only
able to degrade Amonomers. Thus, the striking resultstransgenic animal models can be attenuated by either
peripheral or cerebral infusion of exogenous anti-A for IDE knockout and transgenic mice would imply that
even affecting the metabolism of soluble A monomerantibodies (passive immunization) or by immunization
with synthetic A peptide (DeMattos et al., 2002). Two could have profound effects on A accumulation. The
pathway by which A can be exported across the BBBbasic mechanisms have been proposed to account for
the findings of reduced amyloid load in transgenic ani- into plasma utilizes receptor-mediated efflux via LRP.
Until recently, it had been assumed that transport of Amals with high anti-A antibody titers. First, anti-A anti-
bodies may cross the BBB and bind to A in the brain, via LRP required initial binding to the LRP ligands apoE
and 2M. However, A has very recently been shownprompting digestion by activated microglia. Alterna-
tively, antibodies may bind and sequester A in the to directly bind LRP and then undergo transport across
the BBB. In this case, A40 was more effectively clearedperiphery and either promote efflux from or inhibit influx
back into brain (DeMattos et al., 2002). These intriguing than the more amyloid-prone peptide A42 or a vasculo-
tropic form of the peptide. Thus, direct LRP-mediatedimmunological-based findings also raise the possibility
that the immune system may be involved in the normal removal of A may be limited to the less fibrillogenic
species of the peptide, A40. Meanwhile, A42 may stillclearance of A. The presence of endogenous anti-A
autoantibodies in human plasma suggests similar mech- require prior binding to the LRP ligand/chaperones apoE
and 2M to be effectively transported out of the CNSanisms may operate naturally to facilitate clearance of
A in normal subjects. via LRP.
A can also enter from the bloodstream into the brainAnother therapeutic strategy aimed at clearing cere-
bral A has taken advantage of the fact that metals such primarily via the RAGE receptor. However, it is not clear
what proportion of A that undergoes influx into theas zinc and copper not only drive the aggregation of
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Van Uden, E., Mallory, M., Veinbergs, I., Alford, M., Rockenstein, E.,brain from the plasma was originally generated in the
and Masliah, E. (2002). J. Neurosci. 22, 9298–9304.CNS versus the periphery. This will obviously be an
Yan, S.D., Zhu, H., Zhu, A., Golabek, A., Du, H., Roher, A., Yu, J.,important topic for future studies. The elucidation of
Soto, C., Schmidt, A.M., Stern, D., and Kindy, M. (2000). Nat. Med.the pathways and molecules involved in the removal of
6, 643–651.
cerebral A has already suggested a host of different
Zlokovic, B.V. (2004). J. Neurochem. 89, 807–811.
therapeutic opportunities (summarized in Figure 1). As
Zlokovic, B.V., Martel, C.L., Matsubara, E., McComb, J.G., Zheng,we continue to increase our understanding of the many
G., Mccluskey, R.T., Frangione, B., and Ghiso, J. (1996). Proc. Natl.
roads to perdition for the A peptide, we should also Acad. Sci. USA 93, 4229–4234.
gain valuable clues regarding strategies for treating and
preventing AD based on enhancing the removal of cere-
bral A.
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